Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Liabilities and Shareholders Equity (2018 - 2025)

BioNexus Gene Lab's Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $9.3 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $9.3 million for Q4 2025, down 11.32% from a year ago — trailing twelve months through Dec 2025 was $35.8 million (down 18.19% YoY), and the annual figure for FY2025 was $9.3 million, down 11.32%.
  • Liabilities and Shareholders Equity for Q4 2025 was $9.3 million at BioNexus Gene Lab, up from $7.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $11.5 million in Q3 2023 to a low of $7.6 million in Q3 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $9.5 million (2021), against an average of $9.6 million.
  • The sharpest move saw Liabilities and Shareholders Equity soared 863.76% in 2021, then crashed 30.68% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $9.6 million in 2021, then dropped by 8.71% to $8.7 million in 2022, then skyrocketed by 30.43% to $11.4 million in 2023, then dropped by 8.47% to $10.4 million in 2024, then dropped by 11.32% to $9.3 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $9.3 million, $7.6 million, and $9.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.